As of November 5, 2022, there are currently 459 pharmaceutical listed companies under the first-level industry classification of CITIC Securities of "CS Pharmaceutical", excluding B shares, and 455 pharmaceutical companies have disclosed their third quarterly reports
.
According to statistics, 455 pharmaceutical companies achieved overall revenue of 1.
81 trillion yuan in the first three quarters of 2022, and the total net profit attributable to the parent was 194.
481 billion yuan
.
Among them, 222 pharmaceutical companies achieved double growth
in revenue and net profit in the first three quarters.
In terms of revenue, Shanghai Pharmaceutical, Jointown, Baiyunshan, Sinopharm and Heavy Pharmaceutical Holdings had high
revenue in the first three quarters of this year.
Data show that in the first three quarters of 2022, Shanghai Pharmaceutical's total operating income increased by 8.
5% year-on-year to 174.
612 billion yuan, and the net profit attributable to the parent was 4.
814 billion yuan, a year-on-year increase of 7.
4%.
In the first three quarters of this year, Jointown's operating income increased by 11.
78% year-on-year to 102.
946 billion yuan, and the net profit of non-attributable parent was 1.
515 billion yuan, a year-on-year increase of 15.
08%.
In the first three quarters of this year, Baiyunshan's total operating income increased by 2.
37% year-on-year to 54.
806 billion yuan, and the net profit attributable to the parent increased by 4.
91% year-on-year to 3.
474 billion yuan
.
Sinopharm achieved a year-on-year increase of 8.
8% in operating income in the first three quarters of this year, reaching 54.
617 billion yuan; the net profit attributable to the parent company was 1.
048 billion yuan, a year-on-year decrease of 2.
5%; In the first three quarters of this year, the operating income of Heavy Pharmaceutical Holdings increased by 9.
33% year-on-year to 50.
531 billion yuan, and the net profit attributable to the parent increased by 14.
42% year-on-year to 780 million yuan
.
For Shanghai Pharmaceutical, the industry said that the company's main business operation is stable and the ability to resist risks is strong
.
It is reported that as of the end of the third quarter, Shanghai Pharmaceutical's clinical applications have been accepted and entered the clinical research stage of 53 new drug pipelines, including 43 innovative drugs and 10 improved new drugs
.
Among the innovative drug pipelines, 8 have been in the pivotal research, clinical phase III and follow-up research stages
.
Among them, in the third quarter, 2 new varieties (2 specifications) passed the consistency evaluation of generic drugs, increasing the cumulative number of approved consistency evaluation products to 46 varieties (68 specifications).
This year, Shanghai Pharmaceutical also ranked as the "revenue king"
in the first three quarters with a revenue of 174.
612 billion yuan.
The growth of Jointown's performance was mainly due to the digital transformation and upgrading of its main business, the steady growth of B-end digital distribution and general brand promotion business, and the improvement
of C-end layout and service capabilities.
Jointown said that in the face of the complex and changeable external environment, the challenges of the domestic epidemic at multiple points, and the impact of the normalization of the industry's "volume procurement" policy, the company has forged ahead under pressure, maintained steady growth in overall operating performance, gradually improved the quality of operation, and achieved a great increase
in revenue scale and profitability.
In terms of net profit, according to statistics, Jiuan Medical, Mindray Medical, WuXi AppTec, Zhifei Biotechnology, Daan Genetics, Shanghai Pharmaceutical, Wantai Biotechnology, Mingde Biotechnology, Baiyunshan and Changchun High-tech are the top
A-share listed pharmaceutical companies with net profit attributable to the parent.
Among them, Jiuan Medical achieved revenue and net profit in the first three quarters of this year, up 3010.
77% and 31918.
64% year-on-year, respectively, to 24.
589 billion yuan and 16.
050 billion yuan; in the third quarter, revenue and net profit increased by 497.
31% and 17452.
26% year-on-year to 1.
323 billion yuan and 807 million yuan
, respectively.
Jiuan Medical said that the company's performance rose mainly due to the strong market demand for the company's iHealth kit products in the United States
.
In addition, in the first three quarters of this year, Mindray achieved a net profit attributable to the parent of about 8.
102 billion yuan, a year-on-year increase of more than 20%; WuXi AppTec achieved a net profit attributable to the parent of about 7.
378 billion yuan, a year-on-year increase of 107.
12%; Zhifei Biotech achieved a net profit of about 5.
607 billion yuan, Daan Gene realized a net profit of about 4.
911 billion yuan, Wantai Biotech realized a net profit of about 3.
944 billion yuan, Mingde Biotech realized a net profit of about 3.
838 billion yuan, and Changchun High-tech realized a net profit of about 3.
465 billion yuan
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
